Biovail Targets Paddock Over Aplenzin ANDA

By Liz McKenzie

Law360, New York (March 10, 2010, 5:17 PM ET) -- Biovail Laboratories International SRL has shot off a patent infringement suit against Paddock Laboratories Inc. over its plans to market a generic version of the antidepressant Aplenzin.

Biovail filed the complaint Tuesday in the U.S. District Court for the District of Minnesota, seeking to block the generic-drug maker from bringing its own version of Aplenzin to the market before Biovail's patents expire.

Paddock recently submitted an abbreviated new drug application to the U.S. Food and Drug Administration for approval to sell bupropion hydrobromide extended-release tablets, the...
To view the full article, take a free trial now.

Already a subscriber? Click here to login

You must correct or enter the following before you can submit this form:

All fields required

  5. Required

Only Law360 gives you:

Non-stop coverage of high-stakes litigation across 30 practices

Real-time tracking and reports on 10,000+ companies, firms and industries

Over 80,000 attorney profiles with neutral data collected from active lawsuits

Research tools to find cases, court documents, attorneys and companies

Customized feeds and alerts that can easily be shared with colleagues

In-depth expert analysis from high-profile attorneys at top firms

Access to our vault with over 75,000 original articles